LB100

01/06/2020 - "Inhibition of PP2A with LB-100 Enhances Efficacy of CAR-T Cell Therapy Against Glioblastoma."
07/01/2015 - "LB100 treatment effectively inhibited PP2A activity and enhanced U251 glioblastoma radiosensitivity in vitro and in vivo. "
06/01/2020 - "Inhibition of protein phosphatase-2A with LB-100 enhances antitumor immunity against glioblastoma."
07/01/2015 - "Glioblastoma cells treated with combination LB100 and radiotherapy maintained increased γ-H2AX expression at 24 hours, diminishing cellular repair of radiation-induced DNA double-strand breaks. "
07/01/2015 - "Protein Phosphatase 2A Inhibition with LB100 Enhances Radiation-Induced Mitotic Catastrophe and Tumor Growth Delay in Glioblastoma."

01/01/2018 - "In this study, we demonstrated the therapeutic potency of LB100 in mucoepidermoid carcinoma. "
01/01/2018 - "Importantly, LB100 enhanced the efficacy of cisplatin in mucoepidermoid carcinoma cells both in vitro and in vivo. "
01/01/2018 - "The effects associated with LB100 alone and in combination with cisplatin for the treatment of mucoepidermoid carcinoma were investigated both in vitro, regarding metabolism, proliferation, and migration, and in vivo in a mucoepidermoid carcinoma xenograft model. "
01/01/2018 - "PP2A inhibition by LB100 increased the phosphorylation of insulin receptor substrate 1(IRS-1) on serine residues, downregulated the expression of phosphatidylinositol 3-kinase (PI3K) p110 alpha subunit and dephosphorylated AKT at Ser473 and Thr308 in mucoepidermoid carcinoma cells in response to insulin stimulus. "

12/07/2019 - "LB100 may be a potential therapeutic agent for NAFLD."
12/07/2019 - "Pharmacological inhibition of AMPK was performed to further examine the exact mechanism of LB100 in NAFLD. "
12/07/2019 - "To elucidate the effect and underlying mechanism of LB100 in NAFLD. "
12/07/2019 - "LB100 ameliorates nonalcoholic fatty liver disease via the AMPK/Sirt1 pathway."

06/01/2020 - "We investigated the use of a PP2A inhibitor, LB-100, to enhance antitumor efficacy of PD1 blockade in a syngeneic glioma model. "
06/01/2020 - "C57BL/6 mice were implanted with murine glioma cell line GL261-luc or GL261-WT and randomized into 4 treatment arms: (i) control, (ii) LB-100, (iii) PD1 blockade and (iv) combination. "

11/01/2021 - "In this study, LB100, a PP2A inhibitor for treating solid tumors, was first used to clarify the relationship between PP2A and ERK 1/2. In addition, Western blot was used to examine the levels of p-Raf1 (Ser 259) and p-ERK 1/2 (Thr 202/Tyr 204) in the CPu, hippocampus (Hip) and nucleus accumbens (NAc). "
01/01/2018 - "A recently completed phase I trial of LB100 in solid tumors demonstrated its safety. "
01/01/2015 - "These studies demonstrate the tremendous therapeutic potential of LB100 in a variety of cancer types. "
01/01/2015 - "This review summarizes the pre-clinical studies to date that have demonstrated the anti-cancer activity of LB100 via its chemo- and radio-sensitizing properties. "
01/01/2015 - "Recent studies have shown that LB100, a small-molecule inhibitor of PP2A, sensitizes cancer cells to radiation-mediated DNA damage. "